1. A PHASE II OPEN LABEL STUDY OF NEIHULIZUMAB, AN ANTI-CD162 (PSGL-1) ANTIBODY, IN PATIENTS WITH MODERATE TO SEVERE ACTIVE, ANTI-TNFα AND/OR ANTI-INTEGRIN REFRACTORY ULCERATIVE COLITIS. (26th January 2023) Authors: Rubin, David; Lee, Scott D; Flores, Lucky; Albizu-Angulo, Gustavo; Scherl, Ellen; Saini, Surinder; Cho, Iming; Lin, Shih-Yao; Reed, Simona; Hall, Jesse Journal: Inflammatory bowel diseases Issue: Volume 29(2023)Supplement 1 Page Start: S77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗